Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Harris FRC establishes safety of candidate antiepileptic drug in volunteer studies

Dec. 3, 1998

Final marketing application filed for Ampligen in E.U.

Dec. 3, 1998

Significant protection against ischemic injury in cortex of rats primed with estradiol

Dec. 3, 1998

Gene therapies for neuromuscular diseases pursued by Transgene and AFM

Dec. 2, 1998

ABS receives funding from NIH to support development of Alzheimer's drug

Dec. 1, 1998

Piperidine derivatives from Sanofi useful for neurokinin-dependent pathologies

Dec. 1, 1998

Orion launches entacapone in first markets and updates safety information

Dec. 1, 1998

Naphthylpiperazine antipsychotics synthesized at Faes

Dec. 1, 1998

Guilford presents two new series of NAALADase inhibitors

Nov. 30, 1998

Unimed receives U.S. patent protection for dronabinol in treatment of dementia

Nov. 30, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...